AtriCure (ATRC) Misses Q1 EPS by 3c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG
May 2, 2024 5:25 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $58.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q1 revenue of $108.9M (+16.4% y/y rep, +16.3% y/y cc), above consensus of $106.9M. U.S. Q1 revenue was $90.2M (+15.4% y/y), slightly higher than consensus of $89.5M, and International revenue of $18.6M (+21.5% y/y rep, +21.1% y/y cc) beat consensus of $17.4M. The closely watched U.S. Appendage Management segment reported $35.9M (+11% y/y) in Q1 sales, missing consensus... More
